|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ridge CA, Mcerlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wakelee H, Kelly K and Edelman MJ: 50
Years of progress in the systemic therapy of non-small cell lung
cancer. Am Soc Clin Oncol Educ Book. 177–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhan P, Qian Q and Yu LK: Prognostic value
of COX-2 expression in patients with non-small cell lung cancer: A
systematic review and meta-analysis. J Thorac Dis. 5:40–47.
2013.PubMed/NCBI
|
|
5
|
Sheng M, Zhao Y, Wang F, Li S, Wang X,
Shou T, Luo Y and Tang W: Targeted drugs for unselected patients
with advanced non-small-cell lung cancer: A network meta-analysis.
J Thorac Dis. 8:98–115. 2016.PubMed/NCBI
|
|
6
|
Acunzo M and Croce CM: MicroRNA in cancer
and cachexia-a mini-review. J Infect Dis. 212 Suppl 1:S74–S77.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorel O and Dewals BG: MicroRNAs in large
herpesvirus DNA genomes: Recent advances. Biomol Concepts.
7:229–239. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Zhang G, Li D, Jie Z, Chen H, Xiong
J, Liu Y, Cao Y, Jiang M, Le Z and Tan S: Methylation-associated
silencing of miR-495 inhibit the migration and invasion of human
gastric cancer cells by directly targeting PRL-3. Biochem Biophys
Res Commun. 456:344–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mao Y, Li L, Liu J, Wang L and Zhou Y:
MiR-495 inhibits esophageal squamous cell carcinoma progression by
targeting Akt1. Oncotarget. 7:51223–51236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan L, Yao J and Qiu J: miRNA-495
suppresses proliferation and migration of colorectal cancer cells
by targeting FAM83D. Biomed Pharmacother. 96:974–981. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu Y, Liu WG, Lu JH, Liu ZJ, Li HB, Liu
GJ, She HY, Li GY and Shi XH: LncRNA UCA1 promotes renal cell
carcinoma proliferation through epigenetically repressing p21
expression and negatively regulating miR-495. Tumour Biol.
39:10104283177016322017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan M, Mu X, Liu Z, Tao L, Wang J, Ge J
and Qiu J: microRNA-495 promotes bladder cancer cell growth and
invasion by targeting phosphatase and tensin homolog. Biochem
Biophys Res Commun. 483:867–873. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Wu N, Zheng Q, Feng Y, Yan S, Lv
C, Li S, Wang Y and Yang Y: Evaluation of the 7th edition of the
TNM classification for lung cancer at a single institution. J
Cancer Res Clin Oncol. 140:1189–1195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schimittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehta A, Dobersch S, Romero-Olmedo AJ and
Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer
Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hesse M and Arenz C: MicroRNA maturation
and human disease. Methods Mol Biol 1095. 11–25. 2014. View Article : Google Scholar
|
|
18
|
Salido-Guadarrama I, Romero-Cordoba S,
Peralta-Zaragoza O, Hidalgo-Miranda A and Rodríguez-Dorantes M:
MicroRNAs transported by exosomes in body fluids as mediators of
intercelluar communication in cancer. Onco Targets Ther.
7:1327–1338. 2014.PubMed/NCBI
|
|
19
|
Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G,
Poon WS, Xie D, Lin MC and Kung HF: Transcriptional and epigenetic
regulation of human microRNAs. Cancer Lett. 331:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Song Y, Liu D, Zhao J, Xu J, Ren J,
Hu Y, Wang Z, Hou Y and Zhao G: MiR-495 promotes senescence of
mesenchymal stem cells by targeting Bmi-1. Cell Physiol Biochem.
42:780–796. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Yang Y and Feng Z: Suppression of
microRNA-495 alleviates high-glucose-induced retinal ganglion cell
apoptosis by regulating Notch/PTEN/Akt signaling. Biomed
Pharmacother. 106:923–929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai Z, Wang J, Wang T, Li Y, Zhao X, Wu G,
Yang Y, Deng W and Zhang Z: The MiR-495/Annexin A3/P53 axis
inhibits the invasion and EMT of colorectal cancer cells. Cell
Physiol Biochem. 44:1882–1895. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato
JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A
expression in hepatocellular carcinoma. J Clin Invest. 123:285–298.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang-Verslues WW, Chang PH, Wei PC, Yang
CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY and Lee WH: miR-495
is upregulated by E12/E47 in breast cancer stem cells, and promotes
oncogenesis and hypoxia resistance via downregulation of E-cadherin
and REDD1. Oncogene. 30:2463–2474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu H, Chen X, Wang H, Du Y, Wang Y, Zang
W, Li P, Li J, Chang J, Zhao G and Zhang G: MiR-495 regulates
proliferation and migration in NSCLC by targeting MTA3. Tumour
Biol. 35:3487–3494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang F, Zhao L, Mei D, Jiang L, Geng C, Li
Q, Yao X, Liu Y, Kong Y and Cao J: HMGA2 plays an important role in
Cr (VI)-induced autophagy. Int J Cancer. 141:986–997. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Busch B, Bley N, Müller S, Glaß M, Misiak
D, Lederer M, Vetter M, Strauß HG, Thomssen C and Hüttelmaier S:
The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes
tumor-suppressive actions of the let-7 family. Nucleic Acids Res.
44:3845–3864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin L, Lloyd RV, Henry MR, Erickson LA,
Sebo TJ, Rumilla KM and Zhang J: The diagnostic utility of
combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms.
Appl Immunohistochem Mol Morphol. 23:36–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Zhang Q, Dong JQ, Chang XH and He
XJ: Overexpression of high mobility group A2 and its correlation
with microRNA let-7 family in serous ovarian cancers. Beijing Da
Xue Xue Bao Yi Xue Ban. 44:749–754. 2012.(In Chinese). PubMed/NCBI
|
|
31
|
Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai
H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by
targeting HMGA2 in prostate cancer cells. Mol Cell Biochem.
379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zou Q, Xiong L, Yang Z, Lv F, Yang L and
Miao X: Expression levels of HMGA2 and CD9 and its
clinicopathological significances in the benign and malignant
lesions of the gallbladder. World J Surg Oncol. 10:922012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Q, Lv GD, Qin X, Gen YH, Zheng ST, Liu
T and Lu XM: Role of microRNA let-7 and effect to HMGA2 in
esophageal squamous cell carcinoma. Mol Biol Rep. 39:1239–1246.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding X, Wang Y, Ma X, Guo H, Yan X, Chi Q,
Li J, Hou Y and Wang C: Expression of HMGA2 in bladder cancer and
its association with epithelial-to-mesenchymal transition. Cell
Prolif. 47:146–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meyer B, Loeschke S, Schultze A, Weigel T,
Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2
overexpression in non-small cell lung cancer. Mol Carcinog.
46:503–511. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kong D, Su G, Zha L, Zhang H, Xiang J, Xu
W, Tang Y and Wang Z: Coexpression of HMGA2 and Oct4 predicts an
unfavorable prognosis in human gastric cancer. Med Oncol.
31:1302014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Denechaud PD, Fajas L and Giralt A: E2F1,
a novel regulator of metabolism. Front Endocrinol (Lausanne).
8:3112017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fedele M, Pierantoni GM, Visone R and
Fusco A: E2F1 activation is responsible for pituitary adenomas
induced by HMGA2 gene overexpression. Cell Div. 1:172006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Loukil A, Cheung CT, Bendris N, Lemmers B,
Peter M and Blanchard JM: Cyclin A2: At the crossroads of cell
cycle and cell invasion. World J Biol Chem. 6:346–350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tessari MA, Gostissa M, Altamura S, Sgarra
R, Rustighi A, Salvagno C, Caretti G, Imbriano C, Mantovani R, Del
Sal G, et al: Transcriptional activation of the cyclin A gene by
the architectural transcription factor HMGA2. Mol Cell Biol.
23:9104–9116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
D'Angelo D, Esposito F and Fusco A:
Epigenetic mechanisms leading to overexpression of HMGA proteins in
human pituitary adenomas. Front Med (Lausanne). 2:392015.PubMed/NCBI
|
|
43
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
